Programme (PDF) - (NCRI) Cancer Conference 2013 - National ...

Synthetic lethality: targeting damaged pathways
Hosted by Thomas Helleday
CRUK-MRC Gray Institute for Radiation Oncology and Biology, University of Oxford,
UK
o Thomas Helleday
CRUK- MRC Gray Institute for Radiation Oncology and Biology, University of
Oxford, UK
Introduction
o Thomas Helleday
University of Oxford, UK
Exploiting synthetic lethality in DNA repair for cancer therapy
o Toshiyasu Taniguchi
Fred Hutchinson Cancer Research Center, USA
Secondary mutation of BRCA1/2 as a mechanism of drug
resistance in BRCA1/2-mutated cancer
o Ester Hammond
University of Oxford, UK
Exploiting hypoxia for anti-cancer therapy using a synthetic
context lethality approach
Proffered paper presentations:
o Madeleine Hewish
Institute of Cancer Research, London, UK
Complementary RNA interference and compound screens to
identify novel therapeutic targets for mismatch repair deficient
cancers
o Sarah Martin
Institute of Cancer Research, London, UK
DNA polymerases as potential therapeutic targets for DNA
mismatch repair deficient cancers
o Mohammed Mohammed
University of Nottingham, UK
Development of human apurinic/apyrimidinic endonuclease
(APE1) inhibitors for cancer therapy
Tumour stroma and vasculature
Hosted by Clare Isacke
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research,
London, UK
o Clare Isacke
Breakthrough Breast Cancer Research Centre, The Institute of Cancer
Research, London, UK
Introduction
o Janine Erler
The Institute of Cancer Research, London, UK
Exploring hypoxia-mediated tumour progression
BACR Translational Research Award
o Luigi Naldini
Vita-Salute San Raffaele University, Milan, Italy
New effectors and therapeutic targets in the tumour-stroma
interaction
o William Stallcup
Burnham Institute for Medical Research, La Jolla, USA
NG2 proteoglycan in tumour vascularisation and progression
32